查看購物車
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
2087402

快速診斷市場：全球市場按產品類型、技術、檢體類型、應用和最終用戶分類的預測——2026-2032年

Rapid Diagnostics Market by Product Type, Technology, Sample Type, Application, End User - Global Forecast 2026-2032
出版日期: | 出版商: 360iResearch | 英文 196 Pages | 商品交期: 最快1-2個工作天內

價格

※ 本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

預計到 2032 年，快速診斷市場將成長至 609.4 億美元，複合年成長率為 8.40%。

主要市場統計數據
基準年 2025 346.3億美元
預計年份：2026年 373.8億美元
預測年份 2032 609.4億美元
複合年成長率 (%) 8.40%

快速診斷正在改變醫療系統在需要的地方檢測、分診和管理感染疾病、慢性病以及緊急醫療決策的方式。該市場包括橫向流動化驗、分子即時檢測、免疫檢測、快速抗原檢測、血糖和心臟標記檢測、妊娠和不孕症檢測，以及擴大應用於醫院、零售診所、藥房、檢查室、職場、社區計畫和居家照護機構的連網診斷平台。

這項需求得到了已確定的公共衛生優先事項的支持。世界衛生組織（世衛組織）強調對結核病、愛滋病毒、瘧疾、肝炎、流感、新冠肺炎、性行為感染感染和抗生素抗藥性進行快速檢測，而美國疾病管制與預防中心（疾控中心）和其他國家機構則繼續倡導及時診斷，認為這對於控制、提供適當治療和進行疫情監測至關重要。快速診斷領域最大的機會出現在以下方面：即時檢測可以縮短治療時間、減少不必要的抗生素使用、擴大檢測範圍（使其不再局限於中心實驗室）以及改進公共衛生應對措施的數位化報告。

快速診斷領域的變革性變化

快速診斷領域正從一次性、基於視覺的檢測轉向聯網、多參數同步測量和數據驅動的檢測模式。新冠疫情使得居家檢測和即時檢測更加普及，加深了監管機構對緊急使用授權的理解，並提高了消費者對快速便捷檢測結果的期望。同時，歐盟體外診斷醫療設備法規、美國食品藥物管理局管理局監管架構的演變以及各大醫療系統品質要求的加強，都提高了臨床證據、生產控制、標籤、易用性和上市後性能監測等方面的標準。

人工智慧對快速診斷的累積影響

人工智慧 (AI) 不再只是一項獨立功能，而是正在成為快速診斷整個價值鏈中累積的驅動力。 AI 可輔助進行檢測設計、生物標記發現、基於影像的決策、低濃度分析物訊號增強、自動化品管和工作流程最佳化。在數位顯微鏡、呼吸系統檢測、敗血症風險分層、抗生素使用和連網家庭診斷等領域，AI 可以幫助臨床醫生在臨床背景下解讀快速檢測結果，並確定後續檢測的優先順序。

亞太地區、北美地區、歐洲地區、拉丁美洲地區以及中東和非洲地區的關鍵區域洞察

亞太地區是全球最具活力的快速診斷市場之一，這得益於其龐大的人口基數、對傳染病檢查的高需求、私營醫療保健的蓬勃發展以及政府對國內診斷能力的大力投資。在中國、印度、日本、韓國、澳洲和東協等市場，隨著數位醫療的日益普及和檢測網路的不斷擴展，對分子診斷、快速呼吸道疾病檢測、女性健康篩檢、糖尿病監測和慢性病篩檢等照護現場系統的需求日益成長。

涵蓋東協、海灣合作理事會、歐盟、金磚國家、七國集團和北約的關鍵集團洞察。

在東協市場，快速診斷正透過公共衛生計畫、本地經銷夥伴以及印尼、泰國、越南、馬來西亞、新加坡和菲律賓等國的私營部門發展而不斷擴展。該地區的優先事項包括登革熱、結核病、呼吸道感染疾病、孕產婦健康、抗生素抗藥性監測，以及在都市區檢查室分散、檢測條件不均的地區提供價格合理的即時檢測服務。

主要國家引入快速診斷方法的趨勢

美國透過FDA批准的平台、不斷擴大的零售診所、醫院即時檢測項目、CLIA豁免檢測以及對分子和數位檢測的大力投資，引領快速診斷技術的創新。加拿大在其省級醫療保健系統中強調品質保證的診斷，而墨西哥和巴西則面臨著感染疾病、女性健康、登革熱、呼吸道疾病和慢性病檢測需求的成長，這些需求在依賴廣泛分銷網路和高效採購的公私混合醫療保健系統中得到滿足。

為快速診斷行業的領導者提供的實用建議

產業領導者應優先發展具有臨床差異化的快速診斷技術，這些技術需展現出可衡量的價值，例如加速治療、減輕醫院負擔、促進合理使用抗生素以及提高醫療服務的可及性。產品系列應兼顧可大規模生產的側向層析檢測、分子即時檢測平台、多參數呼吸道檢測、心臟標記檢測、女性健康篩檢、糖尿病監測以及支持可追溯性、品管和報告功能的數位化領先技術。

快速診斷分析的調查方法

本執行摘要基於二手研究和分析三角驗證，檢驗資訊來源涵蓋公共衛生、監管、臨床和產業等多個領域。主要資料來源包括世界衛生組織 (WHO)、美國疾病管制與預防中心 (CDC)、美國食品藥物管理局(FDA)、歐盟委員會、各國衛生署、同行評審期刊以及權威標準化機構的指南和資料集。分析內容包括疾病負擔、監管政策、技術應用、採購模式、報銷趨勢、數位醫療準備以及醫療基礎設施成熟度。

結論：快速診斷的未來

快速診斷正成為現代醫學的策略支柱，它兼具速度快、可及性和可指導臨床決策等優點。這一領域的定義不再僅僅取決於檢測所需時間，而是越來越注重準確性、互聯性、易用性、監管依據、經濟性以及在整個分散式醫療保健環境中改善患者預後的能力。

目錄

第1章：序言

第2章：調查方法

  • 調查設計
  • 研究框架
  • 市場規模預測
  • 數據三角測量
  • 調查結果
  • 調查的前提
  • 研究限制

第3章執行摘要

  • 首席體驗長觀點
  • 市場規模和成長趨勢
  • 2025年市佔率分析
  • FPNV定位矩陣，2025
  • 新的商機
  • 下一代經營模式
  • 產業藍圖

第4章 市場概覽

  • 產業生態系與價值鏈分析
  • 市場動態
  • 波特五力分析
  • PESTLE分析
  • 市場展望
  • 上市策略

第5章 市場洞察

  • 消費者洞察與終端用戶觀點
  • 消費者體驗基準
  • 機會映射
  • 分銷通路分析
  • 價格趨勢分析
  • 監理合規和標準框架
  • ESG與永續性分析
  • 中斷和風險情景
  • 投資報酬率和成本效益分析

第6章：人工智慧的累積影響，2026年

第7章 快速診斷市場：依產品類型分類

  • 裝置
    • 工作檯面
    • 可攜式的
  • 試劑和耗材
  • 檢測套組

第8章：快速診斷市場：依技術分類

  • 免疫檢測
  • 橫向流動化驗
    • 競爭格局
    • 三明治法
  • 分子診斷
    • 等溫擴增
    • PCR

第9章：快速診斷市場：依樣本類型分類

  • 血
    • 全血
    • 血清
    • 電漿
  • 尿
  • 唾液
  • 拭子
    • 鼻腔
    • 鼻咽
    • 咽
  • 航班

第10章 快速診斷市場：依應用分類

  • 心臟標記物
    • 肌酸激酶 Mb
    • 肌紅蛋白
    • 肌鈣蛋白
  • 糖尿病
    • 1型糖尿病
    • 2型糖尿病
  • 感染疾病
    • 細菌感染疾病
    • 寄生蟲感染疾病
    • 病毒感染疾病
  • 腫瘤學

第11章 快速診斷市場：依最終使用者分類

  • 診所
  • 居家照護
  • 醫院
  • 研究所

第12章 快速診斷市場：按地區分類

  • 亞太地區
  • 北美洲
  • 拉丁美洲
  • 歐洲
  • 中東
  • 非洲

第13章 快速診斷市場：依組別分類

  • ASEAN
  • GCC
  • EU
  • BRICS
  • G7
  • NATO

第14章 快速診斷市場：依國家分類

  • 美國
  • 加拿大
  • 墨西哥
  • 巴西
  • 英國
  • 德國
  • 法國
  • 俄羅斯
  • 義大利
  • 西班牙
  • 中國
  • 印度
  • 日本
  • 澳洲
  • 韓國

第15章 競爭格局

  • 市場集中度分析，2025年
    • 濃度比（CR）
    • 赫芬達爾-赫希曼指數 (HHI)
  • 近期趨勢及影響分析，2025 年
  • 2025年產品系列分析
  • 基準分析，2025 年

第16章：公司簡介

  • Abbott Laboratories
  • Abingdon Health plc
  • Access Bio, Inc.
  • Becton, Dickinson and Company
  • Bio-Rad Laboratories, Inc.
  • BioGnost doo
  • bioMerieux SA
  • Chembio Diagnostics, Inc.
  • CTK Biotech, Inc.
  • Danaher Corporation
  • EKF Diagnostics Holdings plc
  • F. Hoffmann-La Roche Ltd.
  • GenBody Inc.
  • Guangzhou Wondfo Biotech Co., Ltd.
  • Hangzhou AllTest Biotech Co., Ltd.
  • Hardy Diagnostics
  • InBios International, Inc.
  • Lepu Medical Technology（Beijing）Co., Ltd.
  • Meridian Bioscience, Inc.
  • OraSure Technologies, Inc.
  • QuidelOrtho Corporation
  • SD Biosensor, Inc.
  • Sekisui Diagnostics, LLC
  • Siemens Healthineers AG
  • SureScreen Diagnostics Ltd
  • Thermo Fisher Scientific Inc.
  • Trinity Biotech plc
Product Code: MRR-035AB9C0DA79

The Rapid Diagnostics Market is projected to grow by USD 60.94 billion at a CAGR of 8.40% by 2032.

KEY MARKET STATISTICS
Base Year [2025] USD 34.63 billion
Estimated Year [2026] USD 37.38 billion
Forecast Year [2032] USD 60.94 billion
CAGR (%) 8.40%

Rapid diagnostics are reshaping how health systems detect, triage, and manage infectious diseases, chronic conditions, and urgent-care decisions at the point of need. The market spans lateral flow assays, molecular point-of-care testing, immunoassays, rapid antigen tests, glucose and cardiac marker testing, pregnancy and fertility testing, and increasingly connected diagnostic platforms used in hospitals, retail clinics, pharmacies, laboratories, workplaces, community programs, and home-care settings.

Demand is supported by verified public-health priorities: the World Health Organization emphasizes faster testing for tuberculosis, HIV, malaria, hepatitis, influenza, COVID-19, sexually transmitted infections, and antimicrobial resistance, while the U.S. CDC and other national agencies continue to promote timely diagnosis as essential to outbreak control, appropriate therapy, and surveillance. The strongest opportunities in rapid diagnostics are emerging where point-of-care testing shortens time to treatment, reduces unnecessary antimicrobial use, expands access outside centralized laboratories, and improves digital reporting for public-health response.

Transformative Shifts in the Rapid Diagnostics Landscape

The rapid diagnostics landscape is moving from single-use, visually read tests toward connected, multiplexed, and data-enabled testing models. COVID-19 normalized at-home and point-of-care testing, accelerated regulatory familiarity with emergency-use pathways, and expanded consumer expectations for fast, convenient results. At the same time, the European Union In Vitro Diagnostic Regulation, evolving U.S. FDA oversight, and stronger quality requirements across major health systems are raising the bar for clinical evidence, manufacturing controls, labeling, usability, and post-market performance monitoring.

Another transformative shift is the convergence of decentralized care and laboratory-grade performance. Molecular point-of-care systems, digital readers, cloud connectivity, and sample-to-answer platforms are enabling faster decisions in emergency departments, primary care, pharmacies, urgent care centers, and remote settings. Procurement is increasingly influenced by total cost of care, interoperability, reimbursement clarity, supply-chain resilience, biosafety, and the ability to support public-health reporting while maintaining clinical accuracy across diverse patient populations.

Cumulative Impact of Artificial Intelligence on Rapid Diagnostics

Artificial intelligence is becoming a cumulative force across the rapid diagnostics value chain rather than a stand-alone feature. AI supports assay design, biomarker discovery, image-based interpretation, signal enhancement for low-concentration analytes, automated quality control, and workflow optimization. In settings such as digital microscopy, respiratory testing, sepsis risk stratification, antimicrobial stewardship, and connected home diagnostics, AI can help clinicians interpret rapid test results in clinical context and prioritize follow-up testing.

The measurable value of AI in rapid diagnostics depends on validated datasets, transparent performance metrics, cybersecurity, privacy protection, and regulatory-grade clinical evidence. Industry leaders are focusing on human-in-the-loop designs, bias evaluation across populations, device traceability, and integration with electronic health records. The highest-impact use cases will be those that improve sensitivity, reduce invalid tests, accelerate triage, detect operational quality issues, and convert rapid diagnostic results into actionable care pathways without increasing clinician burden.

Key Regional Insights Across Asia-Pacific, North America, Europe, Latin America, Middle East & Africa

Asia-Pacific is one of the most dynamic rapid diagnostics regions because of large populations, high infectious-disease testing needs, expanding private healthcare, and government investment in domestic diagnostics capacity. China, India, Japan, South Korea, Australia, and ASEAN markets show rising demand for molecular point-of-care systems, rapid respiratory panels, women's health testing, diabetes monitoring, and chronic disease screening, supported by broader digital health adoption and growing laboratory networks.

North America remains a major innovation and commercialization hub, supported by advanced reimbursement structures, strong hospital networks, pharmacy-based testing, CLIA-waived testing pathways in the United States, and FDA-cleared platforms. Europe is shaped by the EU IVDR, which is increasing evidence requirements while supporting higher confidence in test performance, clinical documentation, and post-market surveillance. Latin America is gaining traction through decentralized testing for dengue, HIV, tuberculosis, sexually transmitted infections, and respiratory infections, although reimbursement, procurement capacity, and last-mile distribution remain uneven. The Middle East is investing in healthcare modernization, national screening programs, and digital health infrastructure, while Africa's rapid diagnostics adoption is strongly linked to malaria, HIV, tuberculosis, maternal health, outbreak preparedness, and donor-supported access initiatives coordinated with national health ministries.

Key Group Insights Covering ASEAN, GCC, European Union, BRICS, G7 & NATO

ASEAN markets are expanding rapid diagnostics through public-health programs, local distribution partnerships, and private-sector growth in Indonesia, Thailand, Vietnam, Malaysia, Singapore, and the Philippines. The region's priorities include dengue, tuberculosis, respiratory infections, maternal health, antimicrobial resistance monitoring, and affordable point-of-care testing in decentralized settings where laboratory access can vary between urban and rural populations.

The GCC is accelerating adoption through hospital modernization, national screening initiatives, medical tourism, and digital health infrastructure in Saudi Arabia, the United Arab Emirates, Qatar, Kuwait, Bahrain, and Oman. The European Union is defined by IVDR compliance, cross-border quality expectations, and demand for clinically validated diagnostics that support antimicrobial stewardship and patient safety. BRICS countries represent high-volume opportunities in infectious disease, chronic disease, and domestic manufacturing, with policy emphasis on healthcare access and local production capacity. G7 markets lead in premium platforms, reimbursement evolution, companion testing integration, and clinical workflow adoption, while NATO countries emphasize preparedness, biosecurity, and resilient diagnostic supply chains for civilian and defense-related health readiness.

Key Country Insights for Rapid Diagnostics Adoption

The United States leads in rapid diagnostics innovation through FDA-cleared platforms, retail-clinic expansion, hospital point-of-care programs, CLIA-waived testing, and strong investment in molecular and digital testing. Canada emphasizes quality-assured diagnostics across provincial health systems, while Mexico and Brazil show growing demand for infectious-disease, women's health, dengue, respiratory illness, and chronic-care testing in mixed public-private systems that depend on distribution reach and procurement efficiency.

In Europe, the United Kingdom, Germany, France, Italy, and Spain are prioritizing validated rapid testing that supports antimicrobial stewardship, respiratory disease management, emergency care, and decentralized healthcare under tighter regulatory expectations. Germany and France benefit from strong laboratory and hospital infrastructure, the United Kingdom emphasizes diagnostic access and care pathway efficiency, and Italy and Spain continue to expand rapid testing for respiratory, cardiovascular, and infectious disease use cases. Russia maintains demand for infectious-disease and hospital diagnostics despite trade, procurement, and supply-chain constraints.

China and India are major rapid diagnostics engines because of scale, domestic manufacturing, high testing volumes, and public-health needs spanning respiratory infections, tuberculosis, hepatitis, diabetes, and maternal health. Japan, South Korea, and Australia are advanced markets with strong quality standards, aging populations, established reimbursement structures, and adoption of connected diagnostic tools. Across these countries, rapid diagnostics adoption depends on clinical accuracy, affordability, reimbursement, distribution reliability, regulatory compliance, local service support, and integration with care pathways.

Actionable Recommendations for Rapid Diagnostics Industry Leaders

Industry leaders should prioritize clinically differentiated rapid diagnostics that prove measurable value in faster treatment, reduced hospital burden, antimicrobial stewardship, and improved access. Product portfolios should balance high-volume lateral flow tests with molecular point-of-care platforms, multiplex respiratory panels, cardiac markers, women's health diagnostics, diabetes monitoring, and digital readers that support traceability, quality control, and reporting.

Organizations should strengthen regulatory readiness for FDA, EU IVDR, and other national requirements by investing in real-world evidence, quality systems, usability studies, analytical validation, clinical validation, and post-market surveillance. Partnerships with pharmacies, primary-care networks, public-health agencies, laboratories, community programs, and telehealth providers can extend reach. Supply-chain localization, AI governance, cybersecurity, reimbursement evidence, and health-equity considerations should be treated as strategic priorities rather than operational afterthoughts.

Research Methodology for Rapid Diagnostics Analysis

This executive summary is based on secondary research and analytical triangulation from verified public-health, regulatory, clinical, and industry sources. Core references include guidance and datasets from the World Health Organization, U.S. CDC, U.S. FDA, European Commission, national health ministries, peer-reviewed journals, and recognized standards bodies. The analysis considers disease burden, regulatory policy, technology adoption, procurement patterns, reimbursement trends, digital health readiness, and healthcare infrastructure maturity.

Insights are synthesized using a top-down and bottom-up research approach that compares macro-level health priorities with product-level adoption indicators. Regional and country assessments consider demographic trends, infectious-disease prevalence, chronic disease needs, healthcare access, local manufacturing capacity, regulatory requirements, and decentralized care adoption. All claims are framed to avoid unsupported market estimates and focus on evidence-backed drivers, restraints, and opportunities in rapid diagnostics.

Conclusion: The Future of Rapid Diagnostics

Rapid diagnostics are becoming a strategic pillar of modern healthcare because they connect speed, access, and actionable clinical decision-making. The category is no longer defined only by test turnaround time; it is increasingly defined by accuracy, connectivity, usability, regulatory evidence, affordability, and the ability to improve patient outcomes across decentralized care settings.

The next phase of development will be led by validated molecular point-of-care systems, AI-enabled interpretation, multiplex testing, home diagnostics, and digitally connected platforms that support surveillance and care coordination. Organizations that combine scientific credibility, scalable manufacturing, regulatory excellence, resilient supply chains, and strong regional partnerships will be best positioned to advance the rapid diagnostics landscape.

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Definition
  • 1.3. Market Segmentation & Coverage
  • 1.4. Years Considered for the Study
  • 1.5. Currency Considered for the Study
  • 1.6. Language Considered for the Study
  • 1.7. Key Stakeholders

2. Research Methodology

  • 2.1. Introduction
  • 2.2. Research Design
    • 2.2.1. Primary Research
    • 2.2.2. Secondary Research
  • 2.3. Research Framework
    • 2.3.1. Qualitative Analysis
    • 2.3.2. Quantitative Analysis
  • 2.4. Market Size Estimation
    • 2.4.1. Top-Down Approach
    • 2.4.2. Bottom-Up Approach
  • 2.5. Data Triangulation
  • 2.6. Research Outcomes
  • 2.7. Research Assumptions
  • 2.8. Research Limitations

3. Executive Summary

  • 3.1. Introduction
  • 3.2. CXO Perspective
  • 3.3. Market Size & Growth Trends
  • 3.4. Market Share Analysis, 2025
  • 3.5. FPNV Positioning Matrix, 2025
  • 3.6. New Revenue Opportunities
  • 3.7. Next-Generation Business Models
  • 3.8. Industry Roadmap

4. Market Overview

  • 4.1. Introduction
  • 4.2. Industry Ecosystem & Value Chain Analysis
    • 4.2.1. Supply-Side Analysis
    • 4.2.2. Demand-Side Analysis
    • 4.2.3. Stakeholder Analysis
  • 4.3. Market Dynamics
    • 4.3.1. Key Drivers
    • 4.3.2. Key Restraints
    • 4.3.3. Key Opportunities
    • 4.3.4. Key Challenges
  • 4.4. Porter's Five Forces Analysis
  • 4.5. PESTLE Analysis
  • 4.6. Market Outlook
    • 4.6.1. Near-Term Market Outlook (0-2 Years)
    • 4.6.2. Medium-Term Market Outlook (3-5 Years)
    • 4.6.3. Long-Term Market Outlook (5-10 Years)
  • 4.7. Go-to-Market Strategy

5. Market Insights

  • 5.1. Consumer Insights & End-User Perspective
  • 5.2. Consumer Experience Benchmarking
  • 5.3. Opportunity Mapping
  • 5.4. Distribution Channel Analysis
  • 5.5. Pricing Trend Analysis
  • 5.6. Regulatory Compliance & Standards Framework
  • 5.7. ESG & Sustainability Analysis
  • 5.8. Disruption & Risk Scenarios
  • 5.9. Return on Investment & Cost-Benefit Analysis

6. Cumulative Impact of Artificial Intelligence 2026

7. Rapid Diagnostics Market, by Product Type

  • 7.1. Instruments
    • 7.1.1. Benchtop
    • 7.1.2. Portable
  • 7.2. Reagents & Consumables
  • 7.3. Test Kits

8. Rapid Diagnostics Market, by Technology

  • 8.1. Immunoassay
  • 8.2. Lateral Flow Assay
    • 8.2.1. Competitive
    • 8.2.2. Sandwich
  • 8.3. Molecular Diagnostics
    • 8.3.1. Isothermal Amplification
    • 8.3.2. Pcr

9. Rapid Diagnostics Market, by Sample Type

  • 9.1. Blood
    • 9.1.1. Whole Blood
    • 9.1.2. Serum
    • 9.1.3. Plasma
  • 9.2. Urine
  • 9.3. Saliva
  • 9.4. Swab
    • 9.4.1. Nasal
    • 9.4.2. Nasopharyngeal
    • 9.4.3. Throat
  • 9.5. Stool

10. Rapid Diagnostics Market, by Application

  • 10.1. Cardiac Markers
    • 10.1.1. Creatine Kinase Mb
    • 10.1.2. Myoglobin
    • 10.1.3. Troponin
  • 10.2. Diabetes
    • 10.2.1. Type 1 Diabetes
    • 10.2.2. Type 2 Diabetes
  • 10.3. Infectious Diseases
    • 10.3.1. Bacterial Infections
    • 10.3.2. Parasitic Infections
    • 10.3.3. Viral Infections
  • 10.4. Oncology

11. Rapid Diagnostics Market, by End User

  • 11.1. Clinics
  • 11.2. Home Care
  • 11.3. Hospitals
  • 11.4. Laboratories

12. Rapid Diagnostics Market, by Region

  • 12.1. Asia-Pacific
  • 12.2. North America
  • 12.3. Latin America
  • 12.4. Europe
  • 12.5. Middle East
  • 12.6. Africa

13. Rapid Diagnostics Market, by Group

  • 13.1. ASEAN
  • 13.2. GCC
  • 13.3. European Union
  • 13.4. BRICS
  • 13.5. G7
  • 13.6. NATO

14. Rapid Diagnostics Market, by Country

  • 14.1. United States
  • 14.2. Canada
  • 14.3. Mexico
  • 14.4. Brazil
  • 14.5. United Kingdom
  • 14.6. Germany
  • 14.7. France
  • 14.8. Russia
  • 14.9. Italy
  • 14.10. Spain
  • 14.11. China
  • 14.12. India
  • 14.13. Japan
  • 14.14. Australia
  • 14.15. South Korea

15. Competitive Landscape

  • 15.1. Market Concentration Analysis, 2025
    • 15.1.1. Concentration Ratio (CR)
    • 15.1.2. Herfindahl Hirschman Index (HHI)
  • 15.2. Recent Developments & Impact Analysis, 2025
  • 15.3. Product Portfolio Analysis, 2025
  • 15.4. Benchmarking Analysis, 2025

16. Company Profiles

  • 16.1. Abbott Laboratories
  • 16.2. Abingdon Health plc
  • 16.3. Access Bio, Inc.
  • 16.4. Becton, Dickinson and Company
  • 16.5. Bio-Rad Laboratories, Inc.
  • 16.6. BioGnost d.o.o.
  • 16.7. bioMerieux SA
  • 16.8. Chembio Diagnostics, Inc.
  • 16.9. CTK Biotech, Inc.
  • 16.10. Danaher Corporation
  • 16.11. EKF Diagnostics Holdings plc
  • 16.12. F. Hoffmann-La Roche Ltd.
  • 16.13. GenBody Inc.
  • 16.14. Guangzhou Wondfo Biotech Co., Ltd.
  • 16.15. Hangzhou AllTest Biotech Co., Ltd.
  • 16.16. Hardy Diagnostics
  • 16.17. InBios International, Inc.
  • 16.18. Lepu Medical Technology (Beijing) Co., Ltd.
  • 16.19. Meridian Bioscience, Inc.
  • 16.20. OraSure Technologies, Inc.
  • 16.21. QuidelOrtho Corporation
  • 16.22. SD Biosensor, Inc.
  • 16.23. Sekisui Diagnostics, LLC
  • 16.24. Siemens Healthineers AG
  • 16.25. SureScreen Diagnostics Ltd
  • 16.26. Thermo Fisher Scientific Inc.
  • 16.27. Trinity Biotech plc

LIST OF FIGURES

  • FIGURE 1. GLOBAL RAPID DIAGNOSTICS MARKET, YEARS CONSIDERED FOR THE STUDY
  • FIGURE 2. GLOBAL RAPID DIAGNOSTICS MARKET, RESEARCH DESIGN
  • FIGURE 3. GLOBAL RAPID DIAGNOSTICS MARKET, RESEARCH FRAMEWORK
  • FIGURE 4. GLOBAL RAPID DIAGNOSTICS MARKET, DATA TRIANGULATION
  • FIGURE 5. GLOBAL RAPID DIAGNOSTICS MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 6. GLOBAL RAPID DIAGNOSTICS MARKET SHARE, BY KEY PLAYER, 2025
  • FIGURE 7. GLOBAL RAPID DIAGNOSTICS MARKET, FPNV POSITIONING MATRIX, 2025
  • FIGURE 8. GLOBAL RAPID DIAGNOSTICS MARKET SIZE, BY PRODUCT TYPE, 2025 VS 2032 (%)
  • FIGURE 9. GLOBAL RAPID DIAGNOSTICS MARKET SIZE, BY PRODUCT TYPE, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 10. GLOBAL RAPID DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2025 VS 2032 (%)
  • FIGURE 11. GLOBAL RAPID DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 12. GLOBAL RAPID DIAGNOSTICS MARKET SIZE, BY SAMPLE TYPE, 2025 VS 2032 (%)
  • FIGURE 13. GLOBAL RAPID DIAGNOSTICS MARKET SIZE, BY SAMPLE TYPE, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 14. GLOBAL RAPID DIAGNOSTICS MARKET SIZE, BY APPLICATION, 2025 VS 2032 (%)
  • FIGURE 15. GLOBAL RAPID DIAGNOSTICS MARKET SIZE, BY APPLICATION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 16. GLOBAL RAPID DIAGNOSTICS MARKET SIZE, BY END USER, 2025 VS 2032 (%)
  • FIGURE 17. GLOBAL RAPID DIAGNOSTICS MARKET SIZE, BY END USER, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 18. GLOBAL RAPID DIAGNOSTICS MARKET SIZE, BY REGION, 2025 VS 2032 (%)
  • FIGURE 19. GLOBAL RAPID DIAGNOSTICS MARKET SIZE, BY REGION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 20. GLOBAL RAPID DIAGNOSTICS MARKET SIZE, BY GROUP, 2025 VS 2032 (%)
  • FIGURE 21. GLOBAL RAPID DIAGNOSTICS MARKET SIZE, BY GROUP, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 22. GLOBAL RAPID DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2025 VS 2032 (%)
  • FIGURE 23. GLOBAL RAPID DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2025 VS 2026 VS 2032 (USD MILLION)

LIST OF TABLES

  • TABLE 1. GLOBAL RAPID DIAGNOSTICS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 2. GLOBAL RAPID DIAGNOSTICS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 3. GLOBAL INSTRUMENTS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 4. GLOBAL INSTRUMENTS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 5. GLOBAL INSTRUMENTS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 6. GLOBAL BENCHTOP MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 7. GLOBAL BENCHTOP MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 8. GLOBAL BENCHTOP MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 9. GLOBAL PORTABLE MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 10. GLOBAL PORTABLE MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 11. GLOBAL PORTABLE MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 12. GLOBAL REAGENTS & CONSUMABLES MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 13. GLOBAL REAGENTS & CONSUMABLES MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 14. GLOBAL REAGENTS & CONSUMABLES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 15. GLOBAL TEST KITS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 16. GLOBAL TEST KITS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 17. GLOBAL TEST KITS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 18. GLOBAL RAPID DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 19. GLOBAL IMMUNOASSAY MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 20. GLOBAL IMMUNOASSAY MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 21. GLOBAL IMMUNOASSAY MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 22. GLOBAL LATERAL FLOW ASSAY MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 23. GLOBAL LATERAL FLOW ASSAY MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 24. GLOBAL LATERAL FLOW ASSAY MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 25. GLOBAL COMPETITIVE MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 26. GLOBAL COMPETITIVE MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 27. GLOBAL COMPETITIVE MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 28. GLOBAL SANDWICH MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 29. GLOBAL SANDWICH MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 30. GLOBAL SANDWICH MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 31. GLOBAL MOLECULAR DIAGNOSTICS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 32. GLOBAL MOLECULAR DIAGNOSTICS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 33. GLOBAL MOLECULAR DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 34. GLOBAL ISOTHERMAL AMPLIFICATION MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 35. GLOBAL ISOTHERMAL AMPLIFICATION MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 36. GLOBAL ISOTHERMAL AMPLIFICATION MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 37. GLOBAL PCR MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 38. GLOBAL PCR MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 39. GLOBAL PCR MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 40. GLOBAL RAPID DIAGNOSTICS MARKET SIZE, BY SAMPLE TYPE, 2018-2032 (USD MILLION)
  • TABLE 41. GLOBAL BLOOD MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 42. GLOBAL BLOOD MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 43. GLOBAL BLOOD MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 44. GLOBAL WHOLE BLOOD MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 45. GLOBAL WHOLE BLOOD MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 46. GLOBAL WHOLE BLOOD MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 47. GLOBAL SERUM MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 48. GLOBAL SERUM MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 49. GLOBAL SERUM MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 50. GLOBAL PLASMA MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 51. GLOBAL PLASMA MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 52. GLOBAL PLASMA MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 53. GLOBAL URINE MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 54. GLOBAL URINE MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 55. GLOBAL URINE MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 56. GLOBAL SALIVA MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 57. GLOBAL SALIVA MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 58. GLOBAL SALIVA MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 59. GLOBAL SWAB MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 60. GLOBAL SWAB MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 61. GLOBAL SWAB MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 62. GLOBAL NASAL MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 63. GLOBAL NASAL MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 64. GLOBAL NASAL MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 65. GLOBAL NASOPHARYNGEAL MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 66. GLOBAL NASOPHARYNGEAL MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 67. GLOBAL NASOPHARYNGEAL MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 68. GLOBAL THROAT MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 69. GLOBAL THROAT MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 70. GLOBAL THROAT MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 71. GLOBAL STOOL MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 72. GLOBAL STOOL MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 73. GLOBAL STOOL MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 74. GLOBAL RAPID DIAGNOSTICS MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 75. GLOBAL CARDIAC MARKERS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 76. GLOBAL CARDIAC MARKERS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 77. GLOBAL CARDIAC MARKERS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 78. GLOBAL CREATINE KINASE MB MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 79. GLOBAL CREATINE KINASE MB MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 80. GLOBAL CREATINE KINASE MB MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 81. GLOBAL MYOGLOBIN MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 82. GLOBAL MYOGLOBIN MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 83. GLOBAL MYOGLOBIN MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 84. GLOBAL TROPONIN MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 85. GLOBAL TROPONIN MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 86. GLOBAL TROPONIN MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 87. GLOBAL DIABETES MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 88. GLOBAL DIABETES MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 89. GLOBAL DIABETES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 90. GLOBAL TYPE 1 DIABETES MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 91. GLOBAL TYPE 1 DIABETES MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 92. GLOBAL TYPE 1 DIABETES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 93. GLOBAL TYPE 2 DIABETES MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 94. GLOBAL TYPE 2 DIABETES MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 95. GLOBAL TYPE 2 DIABETES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 96. GLOBAL INFECTIOUS DISEASES MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 97. GLOBAL INFECTIOUS DISEASES MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 98. GLOBAL INFECTIOUS DISEASES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 99. GLOBAL BACTERIAL INFECTIONS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 100. GLOBAL BACTERIAL INFECTIONS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 101. GLOBAL BACTERIAL INFECTIONS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 102. GLOBAL PARASITIC INFECTIONS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 103. GLOBAL PARASITIC INFECTIONS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 104. GLOBAL PARASITIC INFECTIONS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 105. GLOBAL VIRAL INFECTIONS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 106. GLOBAL VIRAL INFECTIONS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 107. GLOBAL VIRAL INFECTIONS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 108. GLOBAL ONCOLOGY MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 109. GLOBAL ONCOLOGY MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 110. GLOBAL ONCOLOGY MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 111. GLOBAL RAPID DIAGNOSTICS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 112. GLOBAL CLINICS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 113. GLOBAL CLINICS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 114. GLOBAL CLINICS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 115. GLOBAL HOME CARE MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 116. GLOBAL HOME CARE MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 117. GLOBAL HOME CARE MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 118. GLOBAL HOSPITALS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 119. GLOBAL HOSPITALS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 120. GLOBAL HOSPITALS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 121. GLOBAL LABORATORIES MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 122. GLOBAL LABORATORIES MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 123. GLOBAL LABORATORIES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 124. GLOBAL RAPID DIAGNOSTICS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 125. ASIA-PACIFIC RAPID DIAGNOSTICS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 126. ASIA-PACIFIC RAPID DIAGNOSTICS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 127. ASIA-PACIFIC RAPID DIAGNOSTICS MARKET SIZE, BY INSTRUMENTS, 2018-2032 (USD MILLION)
  • TABLE 128. ASIA-PACIFIC RAPID DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 129. ASIA-PACIFIC RAPID DIAGNOSTICS MARKET SIZE, BY LATERAL FLOW ASSAY, 2018-2032 (USD MILLION)
  • TABLE 130. ASIA-PACIFIC RAPID DIAGNOSTICS MARKET SIZE, BY MOLECULAR DIAGNOSTICS, 2018-2032 (USD MILLION)
  • TABLE 131. ASIA-PACIFIC RAPID DIAGNOSTICS MARKET SIZE, BY SAMPLE TYPE, 2018-2032 (USD MILLION)
  • TABLE 132. ASIA-PACIFIC RAPID DIAGNOSTICS MARKET SIZE, BY BLOOD, 2018-2032 (USD MILLION)
  • TABLE 133. ASIA-PACIFIC RAPID DIAGNOSTICS MARKET SIZE, BY SWAB, 2018-2032 (USD MILLION)
  • TABLE 134. ASIA-PACIFIC RAPID DIAGNOSTICS MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 135. ASIA-PACIFIC RAPID DIAGNOSTICS MARKET SIZE, BY CARDIAC MARKERS, 2018-2032 (USD MILLION)
  • TABLE 136. ASIA-PACIFIC RAPID DIAGNOSTICS MARKET SIZE, BY DIABETES, 2018-2032 (USD MILLION)
  • TABLE 137. ASIA-PACIFIC RAPID DIAGNOSTICS MARKET SIZE, BY INFECTIOUS DISEASES, 2018-2032 (USD MILLION)
  • TABLE 138. ASIA-PACIFIC RAPID DIAGNOSTICS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 139. NORTH AMERICA RAPID DIAGNOSTICS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 140. NORTH AMERICA RAPID DIAGNOSTICS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 141. NORTH AMERICA RAPID DIAGNOSTICS MARKET SIZE, BY INSTRUMENTS, 2018-2032 (USD MILLION)
  • TABLE 142. NORTH AMERICA RAPID DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 143. NORTH AMERICA RAPID DIAGNOSTICS MARKET SIZE, BY LATERAL FLOW ASSAY, 2018-2032 (USD MILLION)
  • TABLE 144. NORTH AMERICA RAPID DIAGNOSTICS MARKET SIZE, BY MOLECULAR DIAGNOSTICS, 2018-2032 (USD MILLION)
  • TABLE 145. NORTH AMERICA RAPID DIAGNOSTICS MARKET SIZE, BY SAMPLE TYPE, 2018-2032 (USD MILLION)
  • TABLE 146. NORTH AMERICA RAPID DIAGNOSTICS MARKET SIZE, BY BLOOD, 2018-2032 (USD MILLION)
  • TABLE 147. NORTH AMERICA RAPID DIAGNOSTICS MARKET SIZE, BY SWAB, 2018-2032 (USD MILLION)
  • TABLE 148. NORTH AMERICA RAPID DIAGNOSTICS MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 149. NORTH AMERICA RAPID DIAGNOSTICS MARKET SIZE, BY CARDIAC MARKERS, 2018-2032 (USD MILLION)
  • TABLE 150. NORTH AMERICA RAPID DIAGNOSTICS MARKET SIZE, BY DIABETES, 2018-2032 (USD MILLION)
  • TABLE 151. NORTH AMERICA RAPID DIAGNOSTICS MARKET SIZE, BY INFECTIOUS DISEASES, 2018-2032 (USD MILLION)
  • TABLE 152. NORTH AMERICA RAPID DIAGNOSTICS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 153. LATIN AMERICA RAPID DIAGNOSTICS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 154. LATIN AMERICA RAPID DIAGNOSTICS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 155. LATIN AMERICA RAPID DIAGNOSTICS MARKET SIZE, BY INSTRUMENTS, 2018-2032 (USD MILLION)
  • TABLE 156. LATIN AMERICA RAPID DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 157. LATIN AMERICA RAPID DIAGNOSTICS MARKET SIZE, BY LATERAL FLOW ASSAY, 2018-2032 (USD MILLION)
  • TABLE 158. LATIN AMERICA RAPID DIAGNOSTICS MARKET SIZE, BY MOLECULAR DIAGNOSTICS, 2018-2032 (USD MILLION)
  • TABLE 159. LATIN AMERICA RAPID DIAGNOSTICS MARKET SIZE, BY SAMPLE TYPE, 2018-2032 (USD MILLION)
  • TABLE 160. LATIN AMERICA RAPID DIAGNOSTICS MARKET SIZE, BY BLOOD, 2018-2032 (USD MILLION)
  • TABLE 161. LATIN AMERICA RAPID DIAGNOSTICS MARKET SIZE, BY SWAB, 2018-2032 (USD MILLION)
  • TABLE 162. LATIN AMERICA RAPID DIAGNOSTICS MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 163. LATIN AMERICA RAPID DIAGNOSTICS MARKET SIZE, BY CARDIAC MARKERS, 2018-2032 (USD MILLION)
  • TABLE 164. LATIN AMERICA RAPID DIAGNOSTICS MARKET SIZE, BY DIABETES, 2018-2032 (USD MILLION)
  • TABLE 165. LATIN AMERICA RAPID DIAGNOSTICS MARKET SIZE, BY INFECTIOUS DISEASES, 2018-2032 (USD MILLION)
  • TABLE 166. LATIN AMERICA RAPID DIAGNOSTICS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 167. EUROPE RAPID DIAGNOSTICS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 168. EUROPE RAPID DIAGNOSTICS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 169. EUROPE RAPID DIAGNOSTICS MARKET SIZE, BY INSTRUMENTS, 2018-2032 (USD MILLION)
  • TABLE 170. EUROPE RAPID DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 171. EUROPE RAPID DIAGNOSTICS MARKET SIZE, BY LATERAL FLOW ASSAY, 2018-2032 (USD MILLION)
  • TABLE 172. EUROPE RAPID DIAGNOSTICS MARKET SIZE, BY MOLECULAR DIAGNOSTICS, 2018-2032 (USD MILLION)
  • TABLE 173. EUROPE RAPID DIAGNOSTICS MARKET SIZE, BY SAMPLE TYPE, 2018-2032 (USD MILLION)
  • TABLE 174. EUROPE RAPID DIAGNOSTICS MARKET SIZE, BY BLOOD, 2018-2032 (USD MILLION)
  • TABLE 175. EUROPE RAPID DIAGNOSTICS MARKET SIZE, BY SWAB, 2018-2032 (USD MILLION)
  • TABLE 176. EUROPE RAPID DIAGNOSTICS MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 177. EUROPE RAPID DIAGNOSTICS MARKET SIZE, BY CARDIAC MARKERS, 2018-2032 (USD MILLION)
  • TABLE 178. EUROPE RAPID DIAGNOSTICS MARKET SIZE, BY DIABETES, 2018-2032 (USD MILLION)
  • TABLE 179. EUROPE RAPID DIAGNOSTICS MARKET SIZE, BY INFECTIOUS DISEASES, 2018-2032 (USD MILLION)
  • TABLE 180. EUROPE RAPID DIAGNOSTICS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 181. MIDDLE EAST RAPID DIAGNOSTICS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 182. MIDDLE EAST RAPID DIAGNOSTICS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 183. MIDDLE EAST RAPID DIAGNOSTICS MARKET SIZE, BY INSTRUMENTS, 2018-2032 (USD MILLION)
  • TABLE 184. MIDDLE EAST RAPID DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 185. MIDDLE EAST RAPID DIAGNOSTICS MARKET SIZE, BY LATERAL FLOW ASSAY, 2018-2032 (USD MILLION)
  • TABLE 186. MIDDLE EAST RAPID DIAGNOSTICS MARKET SIZE, BY MOLECULAR DIAGNOSTICS, 2018-2032 (USD MILLION)
  • TABLE 187. MIDDLE EAST RAPID DIAGNOSTICS MARKET SIZE, BY SAMPLE TYPE, 2018-2032 (USD MILLION)
  • TABLE 188. MIDDLE EAST RAPID DIAGNOSTICS MARKET SIZE, BY BLOOD, 2018-2032 (USD MILLION)
  • TABLE 189. MIDDLE EAST RAPID DIAGNOSTICS MARKET SIZE, BY SWAB, 2018-2032 (USD MILLION)
  • TABLE 190. MIDDLE EAST RAPID DIAGNOSTICS MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 191. MIDDLE EAST RAPID DIAGNOSTICS MARKET SIZE, BY CARDIAC MARKERS, 2018-2032 (USD MILLION)
  • TABLE 192. MIDDLE EAST RAPID DIAGNOSTICS MARKET SIZE, BY DIABETES, 2018-2032 (USD MILLION)
  • TABLE 193. MIDDLE EAST RAPID DIAGNOSTICS MARKET SIZE, BY INFECTIOUS DISEASES, 2018-2032 (USD MILLION)
  • TABLE 194. MIDDLE EAST RAPID DIAGNOSTICS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 195. AFRICA RAPID DIAGNOSTICS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 196. AFRICA RAPID DIAGNOSTICS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 197. AFRICA RAPID DIAGNOSTICS MARKET SIZE, BY INSTRUMENTS, 2018-2032 (USD MILLION)
  • TABLE 198. AFRICA RAPID DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 199. AFRICA RAPID DIAGNOSTICS MARKET SIZE, BY LATERAL FLOW ASSAY, 2018-2032 (USD MILLION)
  • TABLE 200. AFRICA RAPID DIAGNOSTICS MARKET SIZE, BY MOLECULAR DIAGNOSTICS, 2018-2032 (USD MILLION)
  • TABLE 201. AFRICA RAPID DIAGNOSTICS MARKET SIZE, BY SAMPLE TYPE, 2018-2032 (USD MILLION)
  • TABLE 202. AFRICA RAPID DIAGNOSTICS MARKET SIZE, BY BLOOD, 2018-2032 (USD MILLION)
  • TABLE 203. AFRICA RAPID DIAGNOSTICS MARKET SIZE, BY SWAB, 2018-2032 (USD MILLION)
  • TABLE 204. AFRICA RAPID DIAGNOSTICS MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 205. AFRICA RAPID DIAGNOSTICS MARKET SIZE, BY CARDIAC MARKERS, 2018-2032 (USD MILLION)
  • TABLE 206. AFRICA RAPID DIAGNOSTICS MARKET SIZE, BY DIABETES, 2018-2032 (USD MILLION)
  • TABLE 207. AFRICA RAPID DIAGNOSTICS MARKET SIZE, BY INFECTIOUS DISEASES, 2018-2032 (USD MILLION)
  • TABLE 208. AFRICA RAPID DIAGNOSTICS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 209. GLOBAL RAPID DIAGNOSTICS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 210. ASEAN RAPID DIAGNOSTICS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 211. ASEAN RAPID DIAGNOSTICS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 212. ASEAN RAPID DIAGNOSTICS MARKET SIZE, BY INSTRUMENTS, 2018-2032 (USD MILLION)
  • TABLE 213. ASEAN RAPID DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 214. ASEAN RAPID DIAGNOSTICS MARKET SIZE, BY LATERAL FLOW ASSAY, 2018-2032 (USD MILLION)
  • TABLE 215. ASEAN RAPID DIAGNOSTICS MARKET SIZE, BY MOLECULAR DIAGNOSTICS, 2018-2032 (USD MILLION)
  • TABLE 216. ASEAN RAPID DIAGNOSTICS MARKET SIZE, BY SAMPLE TYPE, 2018-2032 (USD MILLION)
  • TABLE 217. ASEAN RAPID DIAGNOSTICS MARKET SIZE, BY BLOOD, 2018-2032 (USD MILLION)
  • TABLE 218. ASEAN RAPID DIAGNOSTICS MARKET SIZE, BY SWAB, 2018-2032 (USD MILLION)
  • TABLE 219. ASEAN RAPID DIAGNOSTICS MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 220. ASEAN RAPID DIAGNOSTICS MARKET SIZE, BY CARDIAC MARKERS, 2018-2032 (USD MILLION)
  • TABLE 221. ASEAN RAPID DIAGNOSTICS MARKET SIZE, BY DIABETES, 2018-2032 (USD MILLION)
  • TABLE 222. ASEAN RAPID DIAGNOSTICS MARKET SIZE, BY INFECTIOUS DISEASES, 2018-2032 (USD MILLION)
  • TABLE 223. ASEAN RAPID DIAGNOSTICS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 224. GCC RAPID DIAGNOSTICS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 225. GCC RAPID DIAGNOSTICS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 226. GCC RAPID DIAGNOSTICS MARKET SIZE, BY INSTRUMENTS, 2018-2032 (USD MILLION)
  • TABLE 227. GCC RAPID DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 228. GCC RAPID DIAGNOSTICS MARKET SIZE, BY LATERAL FLOW ASSAY, 2018-2032 (USD MILLION)
  • TABLE 229. GCC RAPID DIAGNOSTICS MARKET SIZE, BY MOLECULAR DIAGNOSTICS, 2018-2032 (USD MILLION)
  • TABLE 230. GCC RAPID DIAGNOSTICS MARKET SIZE, BY SAMPLE TYPE, 2018-2032 (USD MILLION)
  • TABLE 231. GCC RAPID DIAGNOSTICS MARKET SIZE, BY BLOOD, 2018-2032 (USD MILLION)
  • TABLE 232. GCC RAPID DIAGNOSTICS MARKET SIZE, BY SWAB, 2018-2032 (USD MILLION)
  • TABLE 233. GCC RAPID DIAGNOSTICS MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 234. GCC RAPID DIAGNOSTICS MARKET SIZE, BY CARDIAC MARKERS, 2018-2032 (USD MILLION)
  • TABLE 235. GCC RAPID DIAGNOSTICS MARKET SIZE, BY DIABETES, 2018-2032 (USD MILLION)
  • TABLE 236. GCC RAPID DIAGNOSTICS MARKET SIZE, BY INFECTIOUS DISEASES, 2018-2032 (USD MILLION)
  • TABLE 237. GCC RAPID DIAGNOSTICS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 238. EUROPEAN UNION RAPID DIAGNOSTICS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 239. EUROPEAN UNION RAPID DIAGNOSTICS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 240. EUROPEAN UNION RAPID DIAGNOSTICS MARKET SIZE, BY INSTRUMENTS, 2018-2032 (USD MILLION)
  • TABLE 241. EUROPEAN UNION RAPID DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 242. EUROPEAN UNION RAPID DIAGNOSTICS MARKET SIZE, BY LATERAL FLOW ASSAY, 2018-2032 (USD MILLION)
  • TABLE 243. EUROPEAN UNION RAPID DIAGNOSTICS MARKET SIZE, BY MOLECULAR DIAGNOSTICS, 2018-2032 (USD MILLION)
  • TABLE 244. EUROPEAN UNION RAPID DIAGNOSTICS MARKET SIZE, BY SAMPLE TYPE, 2018-2032 (USD MILLION)
  • TABLE 245. EUROPEAN UNION RAPID DIAGNOSTICS MARKET SIZE, BY BLOOD, 2018-2032 (USD MILLION)
  • TABLE 246. EUROPEAN UNION RAPID DIAGNOSTICS MARKET SIZE, BY SWAB, 2018-2032 (USD MILLION)
  • TABLE 247. EUROPEAN UNION RAPID DIAGNOSTICS MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 248. EUROPEAN UNION RAPID DIAGNOSTICS MARKET SIZE, BY CARDIAC MARKERS, 2018-2032 (USD MILLION)
  • TABLE 249. EUROPEAN UNION RAPID DIAGNOSTICS MARKET SIZE, BY DIABETES, 2018-2032 (USD MILLION)
  • TABLE 250. EUROPEAN UNION RAPID DIAGNOSTICS MARKET SIZE, BY INFECTIOUS DISEASES, 2018-2032 (USD MILLION)
  • TABLE 251. EUROPEAN UNION RAPID DIAGNOSTICS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 252. BRICS RAPID DIAGNOSTICS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 253. BRICS RAPID DIAGNOSTICS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 254. BRICS RAPID DIAGNOSTICS MARKET SIZE, BY INSTRUMENTS, 2018-2032 (USD MILLION)
  • TABLE 255. BRICS RAPID DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 256. BRICS RAPID DIAGNOSTICS MARKET SIZE, BY LATERAL FLOW ASSAY, 2018-2032 (USD MILLION)
  • TABLE 257. BRICS RAPID DIAGNOSTICS MARKET SIZE, BY MOLECULAR DIAGNOSTICS, 2018-2032 (USD MILLION)
  • TABLE 258. BRICS RAPID DIAGNOSTICS MARKET SIZE, BY SAMPLE TYPE, 2018-2032 (USD MILLION)
  • TABLE 259. BRICS RAPID DIAGNOSTICS MARKET SIZE, BY BLOOD, 2018-2032 (USD MILLION)
  • TABLE 260. BRICS RAPID DIAGNOSTICS MARKET SIZE, BY SWAB, 2018-2032 (USD MILLION)
  • TABLE 261. BRICS RAPID DIAGNOSTICS MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 262. BRICS RAPID DIAGNOSTICS MARKET SIZE, BY CARDIAC MARKERS, 2018-2032 (USD MILLION)
  • TABLE 263. BRICS RAPID DIAGNOSTICS MARKET SIZE, BY DIABETES, 2018-2032 (USD MILLION)
  • TABLE 264. BRICS RAPID DIAGNOSTICS MARKET SIZE, BY INFECTIOUS DISEASES, 2018-2032 (USD MILLION)
  • TABLE 265. BRICS RAPID DIAGNOSTICS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 266. G7 RAPID DIAGNOSTICS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 267. G7 RAPID DIAGNOSTICS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 268. G7 RAPID DIAGNOSTICS MARKET SIZE, BY INSTRUMENTS, 2018-2032 (USD MILLION)
  • TABLE 269. G7 RAPID DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 270. G7 RAPID DIAGNOSTICS MARKET SIZE, BY LATERAL FLOW ASSAY, 2018-2032 (USD MILLION)
  • TABLE 271. G7 RAPID DIAGNOSTICS MARKET SIZE, BY MOLECULAR DIAGNOSTICS, 2018-2032 (USD MILLION)
  • TABLE 272. G7 RAPID DIAGNOSTICS MARKET SIZE, BY SAMPLE TYPE, 2018-2032 (USD MILLION)
  • TABLE 273. G7 RAPID DIAGNOSTICS MARKET SIZE, BY BLOOD, 2018-2032 (USD MILLION)
  • TABLE 274. G7 RAPID DIAGNOSTICS MARKET SIZE, BY SWAB, 2018-2032 (USD MILLION)
  • TABLE 275. G7 RAPID DIAGNOSTICS MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 276. G7 RAPID DIAGNOSTICS MARKET SIZE, BY CARDIAC MARKERS, 2018-2032 (USD MILLION)
  • TABLE 277. G7 RAPID DIAGNOSTICS MARKET SIZE, BY DIABETES, 2018-2032 (USD MILLION)
  • TABLE 278. G7 RAPID DIAGNOSTICS MARKET SIZE, BY INFECTIOUS DISEASES, 2018-2032 (USD MILLION)
  • TABLE 279. G7 RAPID DIAGNOSTICS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 280. NATO RAPID DIAGNOSTICS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 281. NATO RAPID DIAGNOSTICS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 282. NATO RAPID DIAGNOSTICS MARKET SIZE, BY INSTRUMENTS, 2018-2032 (USD MILLION)
  • TABLE 283. NATO RAPID DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 284. NATO RAPID DIAGNOSTICS MARKET SIZE, BY LATERAL FLOW ASSAY, 2018-2032 (USD MILLION)
  • TABLE 285. NATO RAPID DIAGNOSTICS MARKET SIZE, BY MOLECULAR DIAGNOSTICS, 2018-2032 (USD MILLION)
  • TABLE 286. NATO RAPID DIAGNOSTICS MARKET SIZE, BY SAMPLE TYPE, 2018-2032 (USD MILLION)
  • TABLE 287. NATO RAPID DIAGNOSTICS MARKET SIZE, BY BLOOD, 2018-2032 (USD MILLION)
  • TABLE 288. NATO RAPID DIAGNOSTICS MARKET SIZE, BY SWAB, 2018-2032 (USD MILLION)
  • TABLE 289. NATO RAPID DIAGNOSTICS MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 290. NATO RAPID DIAGNOSTICS MARKET SIZE, BY CARDIAC MARKERS, 2018-2032 (USD MILLION)
  • TABLE 291. NATO RAPID DIAGNOSTICS MARKET SIZE, BY DIABETES, 2018-2032 (USD MILLION)
  • TABLE 292. NATO RAPID DIAGNOSTICS MARKET SIZE, BY INFECTIOUS DISEASES, 2018-2032 (USD MILLION)
  • TABLE 293. NATO RAPID DIAGNOSTICS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 294. GLOBAL RAPID DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 295. UNITED STATES RAPID DIAGNOSTICS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 296. UNITED STATES RAPID DIAGNOSTICS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 297. UNITED STATES RAPID DIAGNOSTICS MARKET SIZE, BY INSTRUMENTS, 2018-2032 (USD MILLION)
  • TABLE 298. UNITED STATES RAPID DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 299. UNITED STATES RAPID DIAGNOSTICS MARKET SIZE, BY LATERAL FLOW ASSAY, 2018-2032 (USD MILLION)
  • TABLE 300. UNITED STATES RAPID DIAGNOSTICS MARKET SIZE, BY MOLECULAR DIAGNOSTICS, 2018-2032 (USD MILLION)
  • TABLE 301. UNITED STATES RAPID DIAGNOSTICS MARKET SIZE, BY SAMPLE TYPE, 2018-2032 (USD MILLION)
  • TABLE 302. UNITED STATES RAPID DIAGNOSTICS MARKET SIZE, BY BLOOD, 2018-2032 (USD MILLION)
  • TABLE 303. UNITED STATES RAPID DIAGNOSTICS MARKET SIZE, BY SWAB, 2018-2032 (USD MILLION)
  • TABLE 304. UNITED STATES RAPID DIAGNOSTICS MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 305. UNITED STATES RAPID DIAGNOSTICS MARKET SIZE, BY CARDIAC MARKERS, 2018-2032 (USD MILLION)
  • TABLE 306. UNITED STATES RAPID DIAGNOSTICS MARKET SIZE, BY DIABETES, 2018-2032 (USD MILLION)
  • TABLE 307. UNITED STATES RAPID DIAGNOSTICS MARKET SIZE, BY INFECTIOUS DISEASES, 2018-2032 (USD MILLION)
  • TABLE 308. UNITED STATES RAPID DIAGNOSTICS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 309. CANADA RAPID DIAGNOSTICS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 310. CANADA RAPID DIAGNOSTICS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 311. CANADA RAPID DIAGNOSTICS MARKET SIZE, BY INSTRUMENTS, 2018-2032 (USD MILLION)
  • TABLE 312. CANADA RAPID DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 313. CANADA RAPID DIAGNOSTICS MARKET SIZE, BY LATERAL FLOW ASSAY, 2018-2032 (USD MILLION)
  • TABLE 314. CANADA RAPID DIAGNOSTICS MARKET SIZE, BY MOLECULAR DIAGNOSTICS, 2018-2032 (USD MILLION)
  • TABLE 315. CANADA RAPID DIAGNOSTICS MARKET SIZE, BY SAMPLE TYPE, 2018-2032 (USD MILLION)
  • TABLE 316. CANADA RAPID DIAGNOSTICS MARKET SIZE, BY BLOOD, 2018-2032 (USD MILLION)
  • TABLE 317. CANADA RAPID DIAGNOSTICS MARKET SIZE, BY SWAB, 2018-2032 (USD MILLION)
  • TABLE 318. CANADA RAPID DIAGNOSTICS MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 319. CANADA RAPID DIAGNOSTICS MARKET SIZE, BY CARDIAC MARKERS, 2018-2032 (USD MILLION)
  • TABLE 320. CANADA RAPID DIAGNOSTICS MARKET SIZE, BY DIABETES, 2018-2032 (USD MILLION)
  • TABLE 321. CANADA RAPID DIAGNOSTICS MARKET SIZE, BY INFECTIOUS DISEASES, 2018-2032 (USD MILLION)
  • TABLE 322. CANADA RAPID DIAGNOSTICS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 323. MEXICO RAPID DIAGNOSTICS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 324. MEXICO RAPID DIAGNOSTICS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 325. MEXICO RAPID DIAGNOSTICS MARKET SIZE, BY INSTRUMENTS, 2018-2032 (USD MILLION)
  • TABLE 326. MEXICO RAPID DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 327. MEXICO RAPID DIAGNOSTICS MARKET SIZE, BY LATERAL FLOW ASSAY, 2018-2032 (USD MILLION)
  • TABLE 328. MEXICO RAPID DIAGNOSTICS MARKET SIZE, BY MOLECULAR DIAGNOSTICS, 2018-2032 (USD MILLION)
  • TABLE 329. MEXICO RAPID DIAGNOSTICS MARKET SIZE, BY SAMPLE TYPE, 2018-2032 (USD MILLION)
  • TABLE 330. MEXICO RAPID DIAGNOSTICS MARKET SIZE, BY BLOOD, 2018-2032 (USD MILLION)
  • TABLE 331. MEXICO RAPID DIAGNOSTICS MARKET SIZE, BY SWAB, 2018-2032 (USD MILLION)
  • TABLE 332. MEXICO RAPID DIAGNOSTICS MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 333. MEXICO RAPID DIAGNOSTICS MARKET SIZE, BY CARDIAC MARKERS, 2018-2032 (USD MILLION)
  • TABLE 334. MEXICO RAPID DIAGNOSTICS MARKET SIZE, BY DIABETES, 2018-2032 (USD MILLION)
  • TABLE 335. MEXICO RAPID DIAGNOSTICS MARKET SIZE, BY INFECTIOUS DISEASES, 2018-2032 (USD MILLION)
  • TABLE 336. MEXICO RAPID DIAGNOSTICS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 337. BRAZIL RAPID DIAGNOSTICS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 338. BRAZIL RAPID DIAGNOSTICS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 339. BRAZIL RAPID DIAGNOSTICS MARKET SIZE, BY INSTRUMENTS, 2018-2032 (USD MILLION)
  • TABLE 340. BRAZIL RAPID DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 341. BRAZIL RAPID DIAGNOSTICS MARKET SIZE, BY LATERAL FLOW ASSAY, 2018-2032 (USD MILLION)
  • TABLE 342. BRAZIL RAPID DIAGNOSTICS MARKET SIZE, BY MOLECULAR DIAGNOSTICS, 2018-2032 (USD MILLION)
  • TABLE 343. BRAZIL RAPID DIAGNOSTICS MARKET SIZE, BY SAMPLE TYPE, 2018-2032 (USD MILLION)
  • TABLE 344. BRAZIL RAPID DIAGNOSTICS MARKET SIZE, BY BLOOD, 2018-2032 (USD MILLION)
  • TABLE 345. BRAZIL RAPID DIAGNOSTICS MARKET SIZE, BY SWAB, 2018-2032 (USD MILLION)
  • TABLE 346. BRAZIL RAPID DIAGNOSTICS MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 347. BRAZIL RAPID DIAGNOSTICS MARKET SIZE, BY CARDIAC MARKERS, 2018-2032 (USD MILLION)
  • TABLE 348. BRAZIL RAPID DIAGNOSTICS MARKET SIZE, BY DIABETES, 2018-2032 (USD MILLION)
  • TABLE 349. BRAZIL RAPID DIAGNOSTICS MARKET SIZE, BY INFECTIOUS DISEASES, 2018-2032 (USD MILLION)
  • TABLE 350. BRAZIL RAPID DIAGNOSTICS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 351. UNITED KINGDOM RAPID DIAGNOSTICS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 352. UNITED KINGDOM RAPID DIAGNOSTICS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 353. UNITED KINGDOM RAPID DIAGNOSTICS MARKET SIZE, BY INSTRUMENTS, 2018-2032 (USD MILLION)
  • TABLE 354. UNITED KINGDOM RAPID DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 355. UNITED KINGDOM RAPID DIAGNOSTICS MARKET SIZE, BY LATERAL FLOW ASSAY, 2018-2032 (USD MILLION)
  • TABLE 356. UNITED KINGDOM RAPID DIAGNOSTICS MARKET SIZE, BY MOLECULAR DIAGNOSTICS, 2018-2032 (USD MILLION)
  • TABLE 357. UNITED KINGDOM RAPID DIAGNOSTICS MARKET SIZE, BY SAMPLE TYPE, 2018-2032 (USD MILLION)
  • TABLE 358. UNITED KINGDOM RAPID DIAGNOSTICS MARKET SIZE, BY BLOOD, 2018-2032 (USD MILLION)
  • TABLE 359. UNITED KINGDOM RAPID DIAGNOSTICS MARKET SIZE, BY SWAB, 2018-2032 (USD MILLION)
  • TABLE 360. UNITED KINGDOM RAPID DIAGNOSTICS MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 361. UNITED KINGDOM RAPID DIAGNOSTICS MARKET SIZE, BY CARDIAC MARKERS, 2018-2032 (USD MILLION)
  • TABLE 362. UNITED KINGDOM RAPID DIAGNOSTICS MARKET SIZE, BY DIABETES, 2018-2032 (USD MILLION)
  • TABLE 363. UNITED KINGDOM RAPID DIAGNOSTICS MARKET SIZE, BY INFECTIOUS DISEASES, 2018-2032 (USD MILLION)
  • TABLE 364. UNITED KINGDOM RAPID DIAGNOSTICS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 365. GERMANY RAPID DIAGNOSTICS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 366. GERMANY RAPID DIAGNOSTICS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 367. GERMANY RAPID DIAGNOSTICS MARKET SIZE, BY INSTRUMENTS, 2018-2032 (USD MILLION)
  • TABLE 368. GERMANY RAPID DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 369. GERMANY RAPID DIAGNOSTICS MARKET SIZE, BY LATERAL FLOW ASSAY, 2018-2032 (USD MILLION)
  • TABLE 370. GERMANY RAPID DIAGNOSTICS MARKET SIZE, BY MOLECULAR DIAGNOSTICS, 2018-2032 (USD MILLION)
  • TABLE 371. GERMANY RAPID DIAGNOSTICS MARKET SIZE, BY SAMPLE TYPE, 2018-2032 (USD MILLION)
  • TABLE 372. GERMANY RAPID DIAGNOSTICS MARKET SIZE, BY BLOOD, 2018-2032 (USD MILLION)
  • TABLE 373. GERMANY RAPID DIAGNOSTICS MARKET SIZE, BY SWAB, 2018-2032 (USD MILLION)
  • TABLE 374. GERMANY RAPID DIAGNOSTICS MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 375. GERMANY RAPID DIAGNOSTICS MARKET SIZE, BY CARDIAC MARKERS, 2018-2032 (USD MILLION)
  • TABLE 376. GERMANY RAPID DIAGNOSTICS MARKET SIZE, BY DIABETES, 2018-2032 (USD MILLION)
  • TABLE 377. GERMANY RAPID DIAGNOSTICS MARKET SIZE, BY INFECTIOUS DISEASES, 2018-2032 (USD MILLION)
  • TABLE 378. GERMANY RAPID DIAGNOSTICS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 379. FRANCE RAPID DIAGNOSTICS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 380. FRANCE RAPID DIAGNOSTICS MARK